PHGE Company Profile and Key Details

AMEX : PHGE

BiomX

$4.56

-0.73-13.80%

At Close 4:00 PM

61.29

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

BiomX Inc. (PHGE) stock declined over -13.80%, trading at $4.56 on AMEX, down from the previous close of $5.29. The stock opened at $5.03, fluctuating between $4.54 and $5.08 in the recent session.

Stock Snapshot

5.29

Prev. Close

6.96M

Market Cap

4.5413

Day Low

-0.13

P/E Ratio

-34.32

EPS (TTM)

-0.46

Cash Flow per Share

5.03

Open

1.53M

Number of Shares

5.077

Day High

51.38%

Free Float in %

0.07

Book Value

87.1K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	5.03	5.10	4.54	4.56	86.7K
Feb 04, 2026	5.58	5.62	4.99	5.29	97.57K
Feb 03, 2026	6.38	6.38	5.60	5.71	97.2K
Feb 02, 2026	5.73	6.68	5.73	6.23	140.7K
Jan 30, 2026	6.97	7.30	5.62	5.72	207.89K
Jan 29, 2026	5.94	8.50	5.94	7.05	1.06M
Jan 28, 2026	6.54	6.79	5.25	6.58	1.09M
Jan 27, 2026	5.89	7.95	5.74	6.95	37.54M
Jan 26, 2026	3.95	4.38	3.89	4.10	15.57M
Jan 23, 2026	3.64	5.50	3.50	4.01	627.53K
Jan 22, 2026	3.17	3.82	2.92	3.57	136.32K
Jan 21, 2026	2.86	3.20	2.79	3.06	59.54K
Jan 20, 2026	2.50	2.96	2.50	2.75	56.74K
Jan 16, 2026	2.61	2.68	2.56	2.68	18.4K
Jan 15, 2026	2.66	2.66	2.50	2.61	34.6K
Jan 14, 2026	2.28	2.70	2.28	2.64	82.91K
Jan 13, 2026	2.26	2.28	2.15	2.27	19.32K
Jan 12, 2026	2.29	2.30	2.20	2.25	41.92K
Jan 09, 2026	2.18	2.28	2.09	2.28	60.89K
Jan 08, 2026	2.21	2.24	2.10	2.24	31.17K

Contact Details

Ness Ziona, 7414003

Israel

https://www.biomx.com 972 723 942377

About Company

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Stock Peers

TBXU

-0.5133-1.45%

Direxion Shares ETF Trust$34.81 PTN

0.13+0.82%

Palatin Technologies, Inc.$16.05 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 ARMP

-0.02-0.25%

Armata Pharmaceuticals, Inc.$8.08 NSRX

-0.25-4.31%

Nasus Pharma Ltd.$5.55 CVM

-0.11-2.20%

CEL-SCI Corporation$4.90 CANF

0.21+5.20%

Can-Fite BioPharma Ltd.$4.25 PLX

0.01+0.34%

Protalix BioTherapeutics, Inc.$2.91 MAIA

-0.23-10.75%

MAIA Biotechnology, Inc.$1.91

Company Overview

BiomX Inc. (AMEX:PHGE) closed at $4.56 USD, losing -$0.73 (-13.80%) from the previous close of $5.29. The stock is currently mid-range between its 52-week high and low $1.50 and $22.06. With a market capitalization of about $6.96 million, BiomX Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.66). Key stats such as the average daily volume over the past year has been around 1.04 million shares, volume is running light vs its 52-week average. Headquartered in Ness Ziona, None, BiomX Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan Eitan Solomon, the company employs approximately 52 people and listed since March 13, 2019. BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

Technical Performance

PHGE has shown mixed momentum, gaining 22.22% over the past week and -75.43% over the past quarter, though year-to-date performance is up 47.06%. Short-term trend indicators are mixed aligned (SMA20 10.48%, SMA50 33.23%, SMA200 -42.38%). The stock’s 14-day RSI is 52.05 (neutral), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.33% below its high and over 203.92% above its low. Average 10-day trading volume of 5.04 million shares is significantly above the 3-month average of 995.61 thousand, indicating heightened recent market interest.

Valuation Metrics

BiomX Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.75 suggesting the stock is closer to book value. The P/FCF stands at -0.26, also above market averages.

Dividend & Fair Value

BiomX Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

BiomX Inc. generated EPS of -$30.68 over the past year. Five-year average earnings growth is 47.4%. Wall Street analysts project EPS growth of 41.2% annually over the next five years. The latest quarter delivered EPS of $0.00. The next quarter is forecast at -$5.06. Next year's EPS is expected at $17.71. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $15.00. The high target offers 470.18% upside. The low target suggests 228.95% downside. The mean target is $21.80. This offers 378.07% upside. BiomX Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -100.0%. The prior quarter beat by -157.58%. Over the last six quarters, Apple has recorded several small beats. These include -158.33% in August 14, 2024.

Shareholding & Insider Activity

BiomX Inc. has 26.55 million shares outstanding. The public float is 18.01 million shares, elevated short interest at 1.91% of float. This equals 501.42 thousand shares. The short ratio is 0.05 days. Institutional investors hold 54.79% of the float. Insiders own 18.81%. OrbiMed Israel BioFund GP Limited Partnership holds 13.77 million shares, Ugwumba Chidozie has 3.00 million shares and Chimovits Erez has 2.31 million shares.

Financial & Profitability Overview

Over the trailing twelve months, BiomX generated - $357.00K in revenue, or - $0.01 per share. Gross margin was 343.98%, operating margin 7754.90%, and net profit margin 7330.25%. Returns are negative, with ROA at -45.00% and ROE at -849.37%.
On valuation metrics, BiomX trades at a P/E of -0.21, P/S of 0.00 and P/B of 0.75. The current ratio is 1.70 and quick ratio is 1.70. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1885.00 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.63, supported by a cash flow-to-debt ratio of -4.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, BiomX posted revenue of - $357.00K, down slightly from - $134.00K in the prior quarter. Gross profit was - $1.23M (margin 343.98%). Operating income was - $27.69M (margin 7754.9%). Net income was- $26.17M (EPS - $0.51).
The company ended the quarter with $15.86M in cash and short-term investments, a total debt of $15.09M, and net debt of - $772.00K. Total assets were $58.16M, with equity of $3.08M. Financials further reflected weakness, with operating cash flow of - $21.29M, free cash flow of - $21.34M, and capital expenditures of - $50.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that BiomX Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 35.09%, with price expected at $6.16 by February 19, 2026, within a range of $4.98 to $7.38 3-Month Outlook: Projected fall of -30.26%, reaching $3.18 by May 05, 2026, with a range of $0.00 to $7.89. 1-Year Outlook: Projected loss of -51.1%, with price at $2.23 by February 05, 2027, within a range of $0.00 to $6.04.

Key Takeaways

BiomX Inc. (AMEX:PHGE) shares are up 47.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BiomX Inc. trading at a premium to the broader market with a P/E of -0.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.00, suggesting 185.09% upside. Our AI forecast model points to short-term strength (35.09% over two weeks), a medium-term fall (-30.26% over three months), and a longer-term loss (-51.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current BiomX Inc. (PHGE) stock price?

BiomX Inc. (AMEX: PHGE) stock price is $4.56 in the last trading session. During the trading session, PHGE stock reached the peak price of $5.08 while $4.54 was the lowest point it dropped to. The percentage change in PHGE stock occurred in the recent session was -13.8% while the dollar amount for the price change in PHGE stock was - $0.73.

PHGE's industry and sector of operation?

The AMEX listed PHGE is part of Biotechnology industry that operates in the broader Healthcare sector. BiomX Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PHGE?

No Data

How PHGE did perform over past 52-week?

PHGE's closing price is 204% higher than its 52-week low of $1.50 where as its distance from 52-week high of $22.06 is -79.33%.

How many employees does PHGE have?

Number of PHGE employees currently stands at 52.

Link for PHGE official website?

Official Website of PHGE is: https://www.biomx.com

How do I contact PHGE?

PHGE could be contacted at phone 972 723 942377 and can also be accessed through its website. PHGE operates from 22 Einstein Street, Ness Ziona, 7414003, Israel.

How many shares of PHGE are traded daily?

PHGE stock volume for the day was 87.1K shares. The average number of PHGE shares traded daily for last 3 months was 1.04M.

What is the market cap of PHGE currently?

The market value of PHGE currently stands at $6.96M with its latest stock price at $4.56 and 1.53M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	52
Beta	1.61
Sales or Revenue	-$357.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PHGE Company Profile and Key Details

BiomX

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Valuation Metrics